{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:38:59Z","timestamp":1781275139821,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12325-025-03308-2","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T06:40:57Z","timestamp":1754462457000},"page":"5023-5041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician\u2019s Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct04181827","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0275-2575","authenticated-orcid":false,"given":"Cyrille","family":"Touzeau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brea","family":"Lipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah M.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seina","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Slaughter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Lendvai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Schecter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-min","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Dytfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Mina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Roeloffzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"3308_CR1","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1038\/leu.2009.147","volume":"23","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase\u00a0III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23:2147\u201352.","journal-title":"Leukemia"},{"key":"3308_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase\u00a03, open-label, multicentre study. Lancet Oncol. 2016;17:27\u201338.","journal-title":"Lancet Oncol"},{"key":"3308_CR3","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"JS Miguel","year":"2013","unstructured":"Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase\u00a03 trial. Lancet Oncol. 2013;14:1055\u201366.","journal-title":"Lancet Oncol"},{"key":"3308_CR4","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","volume":"25","author":"RZ Orlowski","year":"2007","unstructured":"Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase\u00a0III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892\u2013901.","journal-title":"J Clin Oncol"},{"key":"3308_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/bjh.14193","volume":"175","author":"MS Raab","year":"2016","unstructured":"Raab MS, Cavo M, Delforge M, et al. Multiple myeloma: practice patterns across Europe. Br J Haematol. 2016;175:66\u201376.","journal-title":"Br J Haematol"},{"key":"3308_CR6","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase\u00a03 trial. Lancet Oncol. 2014;15:1195\u2013206.","journal-title":"Lancet Oncol"},{"key":"3308_CR7","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S2352-3026(20)30081-8","volume":"7","author":"SZ Usmani","year":"2020","unstructured":"Usmani SZ, Nahi H, Plesner T, et al. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase\u00a02 GEN501 and SIRIUS trials. Lancet Haematol. 2020;7:e447\u201355.","journal-title":"Lancet Haematol"},{"key":"3308_CR8","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.1016\/S2152-2650(22)00570-5","volume":"22","author":"B Dhakal","year":"2022","unstructured":"Dhakal B, Einsele H, Potluri R, et al. P-240: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the SEER-Medicare database. Clin Lymphoma Myeloma Leuk. 2022;22:S167.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3308_CR9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/01.HS9.0000846468.64341.f1","volume":"6","author":"B Dhakal","year":"2022","unstructured":"Dhakal B, Einsele H, Potluri R, et al. P899: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed\/refractory multiple myeloma from the optum database. HemaSphere. 2022;6:790\u20131.","journal-title":"HemaSphere"},{"key":"3308_CR10","volume":"5","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5:e528.","journal-title":"Hemasphere"},{"key":"3308_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/bjh.17888","volume":"196","author":"LG Rodriguez-Lobato","year":"2022","unstructured":"Rodriguez-Lobato LG, Pereira A, Fern\u00e1ndez de Larrea C, et al. Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period. Br J Haematol. 2022;196:649\u201359.","journal-title":"Br J Haematol"},{"key":"3308_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1182\/hematology.2020000109","volume":"2020","author":"N van de Donk","year":"2020","unstructured":"van de Donk N. Sequencing multiple myeloma therapies with and after antibody therapies. Hematology Am Soc Hematol Educ Program. 2020;2020:248\u201358.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3308_CR13","unstructured":"REVLIMID (lenalidomide) [Prescribing information]. Summit, NJ. Celgene Corporation, 2013."},{"key":"3308_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/cancers15010155","volume":"15","author":"F de Arriba de la Fuente","year":"2022","unstructured":"de Arriba de la Fuente F, Montes Gais\u00e1n C, de la Rubia Comos J. How to manage patients with lenalidomide-refractory multiple myeloma. Cancers (Basel). 2022;15:155.","journal-title":"Cancers (Basel)"},{"key":"3308_CR15","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3390\/cancers15030963","volume":"15","author":"P Kulig","year":"2023","unstructured":"Kulig P, Milczarek S, Bakinowska E, Szalewska L, Baumert B, Machalinski B. Lenalidomide in multiple myeloma: review of resistance mechanisms, current treatment strategies and future perspectives. Cancers (Basel). 2023;15:963.","journal-title":"Cancers (Basel)"},{"key":"3308_CR16","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Multiple Myeloma V.1.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed March 31, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"3308_CR17","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Kumar SK, San Miguel J, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22:e105\u201318.","journal-title":"Lancet Oncol"},{"key":"3308_CR18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335\u201347.","journal-title":"N Engl J Med"},{"key":"3308_CR19","doi-asserted-by":"crossref","unstructured":"Mateos M-V, San-Miguel J, Dhakal B, et al. Overall survival with ciltacabtagene autoleucel versus standard of care in lenalidomide-refractory multiple myeloma: phase\u00a03 CARTITUDE-4 study update. Presented at IMS; September 25\u201328, 2024; Rio de Janeiro, Brazil.","DOI":"10.1016\/S2152-2650(24)02346-2"},{"key":"3308_CR20","unstructured":"Janssen Biotech Inc. CARVYKTI\u00ae (ciltacabtagene autoleucel) suspension for intravenous infusion [Prescribing information]. Horsham, PA: Janssen Biotech, Inc., 2024. https:\/\/www.fda.gov\/media\/156560\/download?attachment. Accessed April 1, 2025."},{"key":"3308_CR21","doi-asserted-by":"publisher","first-page":"5062","DOI":"10.1182\/bloodadvances.2024012640","volume":"8","author":"B Dhakal","year":"2024","unstructured":"Dhakal B, Einsele H, Schecter JM, et al. Real-world treatment patterns and outcomes in relapsed\/refractory multiple myeloma (1\u20133 prior lines): Flatiron database. Blood Adv. 2024;8:5062\u201371.","journal-title":"Blood Adv"},{"key":"3308_CR22","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2217\/cer-2022-0045","volume":"11","author":"N Shah","year":"2022","unstructured":"Shah N, Mojebi A, Ayers D, et al. Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma. J Comp Eff Res. 2022;11:737\u201349.","journal-title":"J Comp Eff Res"},{"key":"3308_CR23","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.clml.2022.04.025","volume":"22","author":"K Weisel","year":"2022","unstructured":"Weisel K, Krishnan A, Schecter JM, et al. Matching-adjusted indirect treatment comparison to assess the comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 versus belantamab mafodotin in DREAMM-2, selinexor-dexamethasone in STORM Part 2, and melphalan flufenamide-dexamethasone in HORIZON for the treatment of patients with triple-class exposed relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022;22:690\u2013701.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3308_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jha2.312","volume":"3","author":"T Martin","year":"2022","unstructured":"Martin T, Krishnan A, Yong K, et al. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician\u2019s choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. EJHaem. 2022;3:97\u2013108.","journal-title":"EJHaem"},{"key":"3308_CR25","doi-asserted-by":"publisher","unstructured":"Ma X, Long L, Moon S, Adamson BJS, Baxi SS. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.16.20037143.","DOI":"10.1101\/2020.03.16.20037143"},{"key":"3308_CR26","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691\u20135.","journal-title":"Blood"},{"key":"3308_CR27","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","volume":"21","author":"S Usmani","year":"2016","unstructured":"Usmani S, Ahmadi T, Ng Y, et al. Analysis of real-world data on overall survival in multiple myeloma patients with \u22653 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;21:1355\u201361.","journal-title":"Oncologist"},{"key":"3308_CR28","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083\u2013107.","journal-title":"Stat Med"},{"key":"3308_CR29","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/aje\/kwq439","volume":"173","author":"MJ Funk","year":"2011","unstructured":"Funk MJ, Westreich D, Wiesen C, St\u00fcrmer T, Brookhart MA, Davidian M. Doubly robust estimation of causal effects. Am J Epidemiol. 2011;173:761\u20137.","journal-title":"Am J Epidemiol"},{"key":"3308_CR30","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.clml.2024.03.003","volume":"24","author":"E Kastritis","year":"2024","unstructured":"Kastritis E, Ntanasis-Stathopoulos I, Theodorakakou F, et al. Characteristics and outcomes of patients with relapsed\/refractory multiple myeloma after exposure to lenalidomide in first line of therapy: a single center database review in Greece. Clin Lymphoma Myeloma Leuk. 2024;24:468\u201377.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"3308_CR31","doi-asserted-by":"publisher","first-page":"7200","DOI":"10.1182\/blood-2022-159401","volume":"140","author":"R Hajek","year":"2022","unstructured":"Hajek R, Sliwka H, Stork M, et al. Patient characteristics and survival outcomes of lenalidomide exposed non-refractory vs lenalidomide refractory multiple myeloma patients in the HONEUR Federated Data Network. Blood. 2022;140(Supplement 1):7200\u20132.","journal-title":"Blood"},{"key":"3308_CR32","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1111\/1475-6773.12872","volume":"53","author":"MD Curtis","year":"2018","unstructured":"Curtis MD, Griffith SD, Tucker M, et al. Development and validation of a high-quality composite real-world mortality endpoint. Health Serv Res. 2018;53:4460\u201376.","journal-title":"Health Serv Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03308-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03308-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03308-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:09:16Z","timestamp":1758899356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03308-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3308"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03308-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cyrille Touzeau: Honoraria \u2013 AbbVie, Amgen, Bristol Myers Squibb\/Celgene, Janssen, Pfizer, Sanofi, Takeda; consulting or advisory role \u2013 AbbVie, Amgen, Bristol Myers Squibb\/Celgene, Janssen, Pfizer, Takeda; research funding \u2013 Sanofi (Inst); travel, accommodations, expenses \u2013 Johnson & Johnson\/Janssen, Pfizer, Sanofi. Brea Lipe: Consulting or advisory role \u2013 AbbVie, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Pfizer, Sanofi; research funding \u2013 Amgen. Abdullah M Khan: Speakers\u2019 bureau \u2013 Amgen, Sanofi; research funding \u2013 Bristol Myers Squibb, Sanofi; travel, accommodations, expenses \u2013 Bristol Myers Squibb. Binod Dhakal: Consulting or advisory role \u2013 Amgen, Arcellx, Genentech\/Roche, GlaxoSmithKline, Janssen Oncology, Natera, Pfizer, Sanofi, Pfizer, Takeda; speakers bureau \u2013 Janssen Oncology; honoraria \u2013 Celgene, GlaxoSmithKline, Karyopharm Therapeutics, Sanofi; research funding \u2013 Amgen (Inst), Arcellx (Inst), CARsgen Therapeutics (Inst), Bristol Myers Squibb\/Celgene (Inst), GlaxoSmithKline, Janssen Oncology (Inst), Sanofi (Inst). Man Zhao: Employment \u2013 Haisco Pharmaceutical (I), IQVIA, Janssen; research funding \u2013 Haisco Pharmaceutical (I); patents, royalties, other intellectual property \u2013 Haisco Pharmaceutical (I). Xavier Leleu: Honoraria \u2013 Bristol Myers Squibb, Takeda. Noem\u00ed Puig: Honoraria \u2013 Amgen, Celgene, Janssen, Pfizer, Sanofi, Takeda, The Binding Site; consulting or advisory role \u2013 Amgen, Celgene, Janssen, Pfizer, Sanofi, Takeda, The Binding Site; speakers bureau \u2013 Celgene; research funding \u2013 Amgen, Celgene, Janssen, Pfizer, Takeda; travel, accommodations, expenses \u2013 Amgen, Celgene, Janssen, Pfizer, Takeda, The Binding Site. Dominik Dytfeld: Honoraria \u2013 Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Pfizer; consulting or advisory role \u2013 Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Pfizer; research funding \u2013 Bristol Myers Squibb, Janssen; travel, accommodations, expenses \u2013 Amgen, Janssen, Bristol Myers Squibb, Pfizer. Elena Zamagni: Honoraria and advisory role \u2013 Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Menarini-Stemline, Oncopeptides, Pfizer, Sanofi. Katja Weisel: Honoraria \u2013 AbbVie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen (Inst), Janssen-Cilag, Karyopharm Therapeutics, Menarini, Novartis, Oncopeptides, Pfizer, Roche, Sanofi, Stemline Therapeutics, Takeda; consulting or advisory role \u2013 Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen-Cilag, Karyopharm Therapeutics, Menarini, Oncopeptides, Roche, Sanofi, Takeda; research funding \u2013 AbbVie (Inst), Amgen (Inst), Bristol Myers Squibb\/Celgene (Inst), Celgene (Inst), GlaxoSmithKline (Inst), Janssen-Cilag (Inst), Sanofi (Inst); travel, accommodations, expenses \u2013 Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen-Cilag, Menarini, Takeda. Lionel Karlin: Honoraria \u2013 AbbVie, Amgen, Celgene, Johnson & Johnson, Takeda; consulting or advisory role \u2013 Amgen, Celgene, Johnson & Johnson, Takeda; travel, accommodations, expenses \u2013 Amgen, Johnson & Johnson. Michel Delforge: Honoraria \u2013 Amgen, Bristol Myers Squibb, GlaxoSmithKline, Johnson & Johnson; consulting or advisory role \u2013 Johnson & Johnson. Paolo Corradini: Honoraria \u2013 AbbVie, Amgen, Celgene, Gilead\/Kite, Janssen, Novartis, Roche, Sanofi, Takeda; consulting or advisory role \u2013 AbbVie, ADC Therapeutics, Amgen, BeiGene, Celgene, Daiichi Sankyo, Gilead\/Kite, GlaxoSmithKline, Incyte, Janssen, Kyowa Kirin, Nerviano Medical Science, Novartis, Roche, Sanofi, Takeda. Roberto Mina: Honoraria \u2013 AbbVie, Amgen, Bristol Myers Squibb, Janssen Pharmaceuticals, Sanofi; consulting or advisory role \u2013 Bristol Myers Squibb, GlaxoSmithKline, Janssen-Cilag EMEA, Janssen Pharmaceuticals, Pfizer, Takeda. Wilfried Roeloffzen: Honoraria \u2013 Amgen (Inst), Fondation Sanofi Espoir (Inst), Janssen Biotech (Inst); consulting or advisory role \u2013 Bristol Myers Squibb (Inst); travel, accommodations, expenses \u2013 AbbVie. Surbhi Sidana: Consulting or advisory role \u2013 AbbVie, BiolineRx, Bristol Myers Squibb\/Celgene, Genentech\/Roche, Janssen, Kite\/Gilead, Legend Biotech, Pfizer, Regeneron, Sanofi; research funding \u2013 AbbVie (Inst), Allogene Therapeutics (Inst), Bristol Myers Squibb\/Celgene (Inst), Janssen (Inst), Magenta Therapeutics (Inst), Novartis (Inst). Sandhya Nair, Seina Lee, Carolina Lonardi, and Diana Chen: Employment \u2013 Johnson & Johnson. Jianming He, Jo\u00e3o Mendes, Ana Slaughter, Nikoletta Lendvai, Jordan M Schecter, and Tzu-min Yeh: Employment \u2013 Johnson & Johnson; stock and other ownership interests \u2013 Johnson & Johnson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"CARTITUDE-4 was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Guidelines for Good Clinical Practice. The independent ethics committee or institutional review board at each site approved the protocol (Supplemental Table\u00a0). All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}